The industry is yet to see a return to pre-pandemic levels in non-COVID-related clinical trials. “The biggest impact has been in Phase 1 trials, suggesting that there will be fewer drug candidates to progress into later phases of development,” Dowdeswell said. “That said, we still see high demand for CDMO services to support biotech companies in early-stage development.”
In the following interview, Dowdeswell provides perspective on which small molecule trends the …